{"Clinical Trial ID": "NCT00490646", "Intervention": ["INTERVENTION 1:", "Trastuzumab 2 mg/kg + Ixabepilone 40 mg/m2 IV", "Trastuzumab 4 mg/kg loading dose, then 2 mg/kg per week + ixabepilone 40 mg/m^2 intravenously (IV) over 3 hours once every 21 days (using a 21-day cycle); until disease progression or unacceptable toxicity.", "INTERVENTION 2:", "Trastuzumab 2 mg/kg + Docetaxel 100 mg/m2 IV", "Trastuzumab 4 mg/kg load dose, then 2 mg/kg per week + docetaxel 100 mg/m^2 IV once every 21 days (using a 21-day cycle); until disease progression or unacceptable toxicity."], "Eligibility": ["Incorporation criteria:", "Locally advanced or metastatic, HER2+ breast cancer has not been previously treated with chemotherapy or trastuzumab.", "Subjects who had previously received adjuvant chemotherapy (neo) or trastuzumab were eligible unless they relapsed within 12 months of the last dose of taxane or trastuzumab administered as adjuvant (neo) therapy.", "A Measurable Disease", "- Left ventricular ejection fraction (VEF) 50%", "- Exclusion criteria:", "Previous chemotherapy or trastuzumab for metastatic breast cancer (MBC)", "- Relapse in the following year (neo) adjuvant taxane or trastuzumab", "Neuropathy > Grade 1", "Important cardiovascular diseases", "All brain metastases"], "Results": ["Performance measures:", "Percentage of participants with an objective response (OR; assessed by criteria for assessing responses in solid tumours [RECIST] Version 1.1)", "The percentage of participants with the best overall response (BOR) either the complete response (CR) or the partial response (PR) according to version 1.1 of the RECIST, as determined by the investigator. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from the base value of the sum of the longest diameter (LD) of all lesions. CR and PR criteria should be met again after 4 weeks and before 6 weeks after the initial assessment.", "Time: evaluated every 6 weeks from the start of the study to 12 months; then every 3 months until disease progression (maximum duration of treatment was 108 weeks)", "Results 1:", "Title of arm/group: Trastuzumab 2 mg/kg + Ixabepilone 40 mg/m^2 IV", "Description of the arm/group: trastuzumab 4 mg/kg load dose, then 2 mg/kg per week + ixabepilone 40 mg/m^2 intravenous (IV) over 3 hours once every 21 days (using a 21-day cycle); until disease progression or unacceptable toxicity.", "Total number of participants analysed: 25", "Type of measurement: Number", "Unit of measure: % of participants 60.0 (38.7 to 78.9)", "Results 2:", "Title of arm/group: Trastuzumab 2 mg/kg + Docetaxel 100 mg/m^2 IV", "Description of the arm/group: trastuzumab 4 mg/kg load dose, then 2 mg/kg weekly + docetaxel 100 mg/m^2 IV once every 21 days (using a 21-day cycle); until disease progression or unacceptable toxicity.", "Total number of participants analysed: 25", "Type of measurement: Number", "Unit of measure: percentage of participants 52.0 (31.3 to 72.2)"], "Adverse Events": ["Undesirable Events 1:", "Total: 13/24 (54.17 per cent)", "NEUTROPENIA FEBRILE 5/24 (20.83 %)", "HEMATOXICITY 0/24 (0.00 %)", "NEUTROPENIA 3/24 (12.50%)", "LYMPHADENOPATHY 0/24 (0.00 %)", "PERICARDIAL EFFIRMATION 1/24 (4.17 per cent)", "1/24 (4.17%)", "ALPASIA 0/24 (0.00 %)", "- NAUSEA 0/24 (0.00 %)", "PYREXIA 1/24 (4.17 per cent)", "EXTRAVASATION 0/24 (0.00 %)", "CHOLECYSTITIS 1/24 (4.17 per cent)", "PATHOLOGICAL FRAMEWORK 1/24 (4.17%)", "Adverse Events 2:", "Total: 6/24 (25.0%)", "NEUTROPENIA FEBRILE 0/24 (0.00 %)", "HEMATOXICITY 1/24 (4.17 per cent)", "NEUTROPENIA 0/24 (0.00 %)", "LYMPHADENOPATHY 1/24 (4.17 per cent)", "- PERIOD EFFICIENCY 0/24 (0.00 %)", "ATMOSPHERIC FIBRILLATION 0/24 (0.00 %)", "ALPASIA 1/24 (4.17 per cent)", "NAUSEA 1/24 (4.17 per cent)", "PYREXIA 0/24 (0.00 %)", "EXTRAVASATION 1/24 (4.17 per cent)", "CHOLECYSTITIS 0/24 (0.00 %)", "- PATHOLOGICAL FRAMEWORK 0/24 (0.00 %)"]}